Literature DB >> 12184644

Familial amyloidosis cutis dyschromica: six cases from three families.

Charoen Choonhakarn1, Siriporn Wittayachanyapong.   

Abstract

Amyloidosis cutis dyschromica, a rare form of primary cutaneous amyloidosis requiring histopathological confirmation, is characterized by generalized, asymptomatic hyperpigmentation intermingled with several hypopigmented spots without papulation, atrophy, and telangiectasia. Its onset usually begins before puberty. We describe six patients from three families, four male and two female. The mean age at onset was 10.2 years. Although the skin eruptions had developed extensively since childhood, systemic involvement was not evident even after long-term follow-up. Due to its unique and characteristic features, this condition should be considered as a separate entity and differentiated from other variants of primary cutaneous amyloidosis. The familial occurrence in our report suggests a genetic causal factor in this disease.

Entities:  

Mesh:

Year:  2002        PMID: 12184644     DOI: 10.1111/j.1346-8138.2002.tb00302.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

1.  Amyloidosis cutis dyschromica.

Authors:  Swetha S Kurian; Reena Rai; Subbarao Tadury Madhukar
Journal:  Indian Dermatol Online J       Date:  2013-10

2.  Amyloidosis cutis dyschromica.

Authors:  Jianjun Qiao; Hong Fang; Hongtian Yao
Journal:  Orphanet J Rare Dis       Date:  2012-12-12       Impact factor: 4.123

3.  Amyloidosis cutis dyschromica in two female siblings: cases report.

Authors:  Wenlin Yang; Yangyang Lin; Jian Yang; Wensheng Lin
Journal:  BMC Dermatol       Date:  2011-02-15

4.  Amyloidosis Cutis Dyschromica: A Rare Reticulate Pigmentary Dermatosis.

Authors:  Shyam Verma; Rajiv Joshi
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

5.  Reticulate dermatoses.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian J Dermatol       Date:  2014-01       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.